Tag - ADHD

Developments

KemPharm presents patient-friendly dosing data for KP415 in ADHD

KemPharm (NASDAQ:KMPH) presented study results demonstrating the ability of KP415 to be administered without regard to food and via alternative dosing methods at the annual American Academy of Child and Adolescent...

October 23, 2019

Feature

KemPharm sees license deal, debt restructuring as transformative events

KemPharm (NASDAQ:KMPH) hit a home run last month when it inked a transformative licensing deal of up to $493-million with an affiliate of Gurnet Point Capital, a private equity firm focused on the life science sector...

October 15, 2019

Feature

Alcobra’s ADHD program moving to pediatrics

By Len Zehr With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric...

January 14, 2014

Tag - ADHD

KemPharm presents patient-friendly dosing data for KP415 in ADHD

KemPharm sees license deal, debt restructuring as transformative events

Alcobra’s ADHD program moving to pediatrics

General

More